Skip to main content

Table 6 Therapeutic management during the stay in the ICU

From: Clinical and epidemiologic characterization of patients with systemic lupus erythematosus admitted to an intensive care unit in Colombia

Therapeutic treatment N = 45
n(%)
Required antibiotic 31 (68,9)
 • Carbapenem 15 (33,1)
 • Piperacillin / tazobactam 12 (26,7)
 • Vancomycin 10 (22,2)
 • Ceftriaxone 7 (15,5)
 • Ampicillin sulbactam 5 (11,1)
 • Anti MRSA does not vancomycin * 5 (11,1)
 • Ciprofloxacin 4 (8,9)
 • Tuberculosis treatment 3 (6,7)
 • Cefazolin 3 (6,7)
 • Clarithromycin 2 (4,4)
 • Polymyxin B 1 (2,2)
 • Penicillin 1 (2,2)
Required Antifungal 7 (15,5)
 • Fluconazole 4 (8,9)
 • Voriconazole 2 (4,4)
 • Caspofungin 1 (2,2)
 • Anidulafungin 1 (2,2)
Immunosuppression
 • Pulses Methylprednisolone 22 (48,9)
 • Cyclophosphamide 18 (40,0)
 • Immunoglobulin 7 (15,5)
 • Rituximab 3 (6,7)
Supports
 • Mechanical ventilation 14 (31,1)
 • Days, Medium (RIQ) 5,5 (3–17,75)
 • Dialytic support 16 (35,5)
 • Vasopressor support 9 (20,0)
Procedures 17 (37,7)
Red blood cells transfusion 31 (68,9)
Platelet aferesis 7 (15,5)
Fresh frozen plasma 8 (17,7)
Plasmaferesis 1 (2,2)
  1. * Anti MRSA not vancomycin (Daptomycin, clindamycin and linezolid)